A simple blood test may reduce mortality in heart failure patients
Researchers at the University of California in Los Angeles found out that the blood level of B-type natriuretic peptide (BNP), a neurohormone released by the heart when it is stressed or damaged, provided a direct relationship with in-hospital mortality. So a simple blood test can predict in-hospital mortality risk for heart failure patients.
The test taken at hospital admission maybe useful in helping doctors decide which patients need higher-level monitoring and more intensive treatment.
The relationship between BNP and mortality persisted independent of other clinical and laboratory factors and held true for hospitalized heart failure patients with either reduced or preserved systolic function, which is the ability of the heart´s left ventricle to pump blood to the body´s other organs.
Researchers found that BNP levels remained predictive of mortality even after adjustment for age, gender, systolic blood pressure, pulse and other lab tests, such as blood urea nitrogen, creatinine and sodium.
Higher BNP levels were also predictive of other clinical outcomes, such as the need for mechanical ventilation, the length of the hospital stay and the amount of time spent in the intensive care unit.
Measuring the BNP levels may be a useful addition to routine assessment and can help guide care and treatment of patients hospitalized with acute heart failure. The BNP test provide quick results, often within 15 minutes to a few hours, which can provide physicians with additional information to help in medical decision-making.
A new study proposes a new antiviral strategy against SARS-CoV-2 based on a treatment that combines two complementary approaches, capable of attacking the virus simultaneously.
Article • Avoiding mistakes in design, equipment, validation, and operation
Microbiological cleanliness in laboratories demands far more than routine disinfection – it requires a comprehensive contamination control strategy from the very first design stage. At the Labs…
Why does the same genetic mutation cause FCDII in some patients but not in others? Researchers developed organoids to model a brain malformation responsible for drug-resistant epilepsy in children.
This website uses cookies to give our readers the best website experience. Please refer to our privacy policy to find out how we use cookies and how you can edit your preferences.